Next generation sequencing has greatly enhanced our capability to identify mutations associated with myeloid malignancies. However, accurate and timely detection of complex variants can be challenging.
Microsatellite Instability: how do microsatellites mutations correlate with cancer?
Learn about the technology behind the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution from the lead developer, Dr. Christian Pozzorini.
Learn about the impact of HRD on cancer development, how HRD status may predict sensitivity to certain treatments, and the different HRD testing methods available.
